Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-filled blisters.

Bullous pemphigoid is a rare autoimmune disease that affects your skin. It’s a chronic disease that causes itchy, fluid-filled blisters to form all over your body. Although people of all ages, ...

Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

Please provide your email address to receive an email when new articles are posted on . 50% of patients treated with dupilumab achieved complete remission of blistering lesions. Sixteen patients ...

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

Jim Flaherty, Canada's former finance minister who died of an apparent heart attack on Thursday at age 64, suffered from a rare skin disease called bullous pemphigoid. The politician revealed in ...

Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. This "Bullous pemphigoid - Pipeline ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to monitor ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

An 86-year-old man with a 7-month history of widespread pruritic bullae was referred to our dermatology clinic by his family physician. Physical examination showed tense bullae on his trunk and ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.